Last updated: May 24, 2026
finamide Mesylate Suppliers: Who Manufactures the API, Who Makes Drug Product, and Where Supply Concentrations Sit
Safinamide mesylate is a specialty neurology drug (Parkinson’s disease). Supplier mapping for safinamide mesylate depends on whether you need the API (drug substance), finished tablets/capsules (drug product), or secondary packaging and contract manufacturing.
Important limitation: sufficient, citable public sourcing data (API DMFs, Orange Book drug-product listings tied to specific manufacturers, and validated CMO/CM(C)RO supply contracts) is not available in the provided information to produce a complete, accurate supplier list without risking errors.
What companies supply safinamide mesylate (API and drug product)?
No validated, citable supplier set can be produced from the information available here without inventing company-specific manufacturing roles (API maker vs. finished-dose manufacturer vs. packer).
Which roles matter for safinamide mesylate sourcing
- API (drug substance) manufacturer under DMF
- Finished-dose manufacturer listed on regulatory filings / product label
- Secondary packaging and release site (where applicable)
- Cold-chain or controlled-environment needs (if any) for specific forms (not provided)
How to identify safinamide mesylate suppliers from FDA Orange Book listings?
Orange Book–based identification requires the drug’s FDA application number (NDA/ANDA/BLA) and the listed applicants/manufacturers for each strength/dosage form. Those identifiers are not provided here, so a correct extraction cannot be performed.
What to look for
- Orange Book “Applicant Holder” and “Manufacturer” for each dosage form/strength
- Patent-to-product mapping that sometimes correlates with filing parties and sites
Which DMF holders manufacture safinamide mesylate API?
DMF-holder mapping requires the relevant safinamide mesylate DMF numbers and the referenced applicants. Those DMF identifiers are not provided here, so the DMF-to-company step cannot be completed accurately.
Are there multiple suppliers for safinamide mesylate, or is supply concentrated?
A concentration assessment requires at least two of the following, none of which are provided:
- multiple approved sites with different manufacturers for the same dosage form
- multiple DMFs for the same API with different holders
- contract manufacturing disclosures tied to marketed product labeling
What generic or biosimilar risks change safinamide mesylate supplier options?
Safinamide is a small-molecule, not a biologic, so “biosimilar” does not apply. Generic supply diversification still requires ANDA/505(b)(2) development data and Orange Book manufacturer changes; those inputs are not provided.
Which jurisdictions have safinamide mesylate supply networks for launch and distribution?
Jurisdictional supplier mapping requires country-level label/manufacturer pages (EMA, local PIC/S site registries, customs/importer disclosures). None are provided.
How do you qualify safinamide mesylate suppliers for regulated manufacture?
Qualification depends on access to:
- site audit history
- GMP certifications
- CoA requirements for identity/purity
- impurity profiles and specifications
No supplier/site data is provided to anchor these steps to named vendors.
Safinamide mesylate supply chain: API to finished dosage form (standard model)
A correct supplier workflow depends on the actual listed sites for safinamide product and the API DMF. Without those, a named-supplier chain cannot be stated.
Typical interfaces
- API DMF referenced by the finished-dose application
- finished-dose manufacturer releases per GMP
- distributor/wholesaler moves inventory to regional markets
Key Takeaways
- No complete, accurate named supplier list for safinamide mesylate API and drug product can be produced from the provided information.
- Supplier identification requires FDA/EMA listing identifiers and/or DMF references that are not included here.
- Any named list would carry a high risk of misattributing manufacturing roles.
FAQs
- How can I find the safinamide mesylate API DMF holder?
- Which FDA Orange Book fields identify safinamide mesylate finished-dose manufacturers?
- What evidence distinguishes API suppliers from finished-dose CMOs on regulatory listings?
- Do safinamide mesylate tablet strengths have different manufacturing sites?
- What documents do regulators expect for qualifying an alternate supplier of safinamide mesylate API?
References (APA)
No sources were cited because no verifiable supplier-list inputs (FDA application number, Orange Book entry identifiers, DMF numbers, or label manufacturer/site details) were provided.
